-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 17, AstraZeneca announced a partnership with RQ Biotechnology to introduce an early-stage novel coronavirus monoclonal antibo.
From: official website of the company
With the deal, London-based RQ Biotechnology announced tod.
Previously, AstraZeneca has a long-acting neutralizing antibody combination AZD7442 (Evusheld, Tixagevimab + Cilgavimab) approved for marketing, for severely immunocompromised adults and adolescents over the age of 12 and those who should not be vaccinated against the new crown vaccine or immune response to the new crown vaccine Pre-exposure prophylaxis for underrepresented populatio.
AZD7442 is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061), extracted from B cells of convalescent patients infected with SARS-CoV-2 vir.
Approval of the drug is based on data from the Phase III PROVENT stu.
6-month follow-up data from prevention trials show that a one-time intramuscular injection of the long-acting antibody combination reduces the risk of symptomatic COVID-19 by 83%; separate treatment trials show that treatment within three days of symptom onset reduces the risk of severe COVID-19 The risk of -19 or death was reduced by 8
In addition to the PROVENT study for prevention in high-risk patients, AstraZeneca started the Phase III TACKLE study in outpatients, announcing its positive results in mid-November 202
